100 Campus Drive
Suite 102
Florham Park, NJ 07932
United States
877 742 8466
https://www.phathompharma.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 452
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Ms. Terrie J. Curran | President, CEO & Director | 1.22M | N/A | 1969 |
Mr. David A. Socks | Co-Founder & Director | 54.17k | N/A | 1975 |
Dr. Azmi Nabulsi M.D., M.P.H. | Co-Founder & COO | 888.9k | N/A | 1960 |
Ms. Molly Henderson CPA, MBA | Chief Financial & Business Officer | 777.76k | N/A | 1971 |
Dr. Aditya Kohli Ph.D. | Co-Founder | 319.65k | N/A | 1988 |
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 8; Compensation: 9.